abilify- aripiprazole tablet abilify- aripiprazole solution abilify- aripiprazole tablet, orally disintegrating abilify- arip
otsuka america pharmaceutical, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - abilify (aripiprazole) oral tablets, orally-disintegrating tablets, and oral solution are indicated for the treatment of: - schizophrenia - acute treatment of manic and mixed episodes associated with bipolar i disorder - adjunctive treatment of major depressive disorder - irritability associated with autistic disorder - treatment of tourette's disorder abilify injection is indicated for the treatment of: - agitation associated with schizophrenia or bipolar mania abilify is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including abilify, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhea
ocufen flurbiprofen sodium dihydrate 0.03% eye drops
abbvie pty ltd - flurbiprofen sodium dihydrate, quantity: 0.3 mg/ml - eye drops, solution - excipient ingredients: polyvinyl alcohol; potassium chloride; sodium chloride; sodium citrate dihydrate; citric acid monohydrate; disodium edetate; thiomersal; sodium hydroxide; hydrochloric acid; purified water - for the inhibition of intraoperative miosis.
biphozyl solution for haemodialysis / haemofiltration
baxter holding b.v. - magnesium chloride hexahydrate; sodium chloride; sodium hydrogen carbonate; potassium chloride; disodium phosphate dihydrate - solution for haemodialysis/haemofiltration - hemofiltrates
unique ph solution
alcon canada inc - disodium edetate; polyquaternium 1 - solution - 0.01%; 0.0011% - disodium edetate 0.01%; polyquaternium 1 0.0011% - contact lens solutions
potassium dihydrogen phosphate 1.701% / potassium hydroxide 0.14% (total potassium 7.5mmol/50ml) / disodium phosphate dihydrate 667.5mg solution for infusion 50ml pre-filled syringes
total potassium 7.5mmol/50ml) / disodium phosphate dihydrate 667.5mg solution for infusion 50ml pre-filled syringes (special order - disodium phosphate dihydrate; potassium hydroxide; potassium dihydrogen phosphate - solution for infusion - 13.35mg/1ml ; 1.4mg/1ml ; 17.01mg/1ml
chromium(51cr) edetate 3.7mbq/ml injection
ge healthcare australia pty ltd - chromium(51cr) edetate -
disodium edetate 3g + sodium ascorbate 5g solution in 50ml
disodium edetate; sodium ascorbate -
disodium edetate solution 3g in 100ml
disodium edetate -
disodium tiludronate
ceva animal health pty ltd - disodium tiludronate - unknown - disodium tiludronate biphosphonate active 0.0 - active constituent
disodium methylarsonate
ancom australia pty. limited - disodium methylarsonate = dsma - unknown - disodium methylarsonate = dsma mineral-arsenic active 0.0 - active constituent